# US 2008/0188400 A1 · Methods For Treating Bleeding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188400 A1
- Document ID: US20080188400A1
- Status: Published application
- Kind: A1
- Application number: 11/912,484
- Filed: 2006-04-25
- Published: 2008-08-07
- Earliest claimed: 2005-04-26
- Assignees: Maxygen Holdings Ltd.
- Inventors: Mads Ropke; Stephanie J. Lathrop
- Web page: https://patentgrep.com/patent/US20080188400A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for the treatment of various bleeding disorders using variants of human Factor VII (hFVII) or activated FVII (FVIIa) having an altered activity compared to 5 recombinant FVIIa with the native human sequence.

## Claims

### Claim 1

A method for treatment of bleeding in a patient, wherein the bleeding is associated with trauma, intracerebral hemorrhage (ICH), traumatic brain injury (TBI), burns, variceal bleeds, gastrointestinal bleeding, surgical bleeds, transplantation, fibrinolytic treatment, anticoagulant treatment, postpartum hemorrhage, viral-induced hemorrhage, thrombocytopenia, or factor deficiency, comprising administering to said patient a variant of a human FVII or FVIIa polypeptide that differs from SEQ ID NO:1 in 1-15 amino acid residues and has an increased phospholipid membrane binding affinity and/or an increased tissue factor independent activity relative to hFVIIa.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polypeptide variant comprises at least one amino acid modification in the Gla domain.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polypeptide variant comprises at least one amino acid substitution in a position selected from the group consisting of residues 10, 11, 28, 32, 33, 34, 36 and 38.

### Claim 4 (depends on 3)

The method of claim 3, wherein the polypeptide variant comprises a substitution of a glutamine, a glutamic acid, an aspartic acid or an asparagine residue in position 10.

### Claim 5 (depends on 3)

The method of claim 3, wherein the polypeptide variant comprises a substitution of a glutamic acid or an aspartic acid residue in position 32.

### Claim 6 (depends on 3)

The method of claim 3, wherein the polypeptide variant comprises the substitutions P10Q+K32E.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polypeptide variant comprises at least one substitution selected from the group consisting of R28E/F, D33I3/LM/V/F/Y/W, A34E/D/I/L/MIVN/FY/W, R36E/D, and K38E/D.

### Claim 8 (depends on 7)

The method of claim 7, wherein the polypeptide variant comprises the substitution A34E/L and/or R36E.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polypeptide variant comprises an insertion of at least one amino acid residue between position 3 and 4.

### Claim 10 (depends on 9)

The method of claim 9, wherein the polypeptide variant comprises the insertion A3AY.

### Claim 11 (depends on 1)

The method of claim 1, wherein the polypeptide variant comprises at least one introduced in vivo N-glycosylation site relative to SEQ ID NO:1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the polypeptide variant comprises up to five introduced in vivo N-glycosylation sites relative to SEQ ID NO:1.

### Claim 13 (depends on 11)

The method of claim 11, wherein the polypeptide variant comprises at least one introduced in vivo N-glycosylation site created by a substitution selected from the group consisting of A51N, G58N, T106N, K109N, G124N, K143N+N145T, A175T, I205S, I205T, V253N, T267N, T267N+S269T, S314N+K316S, S314N+K316T, R315N+V317S, R315N+V317T, K316N+G318S, K316N+G318T, G318N and D334N.

### Claim 14 (depends on 13)

The method of claim 13, wherein the polypeptide variant comprises at least one introduced in vivo N-glycosylation site created by a substitution selected from the group consisting of T106N, I205T and V253N.

### Claim 15 (depends on 14)

The method of claim 14, wherein the polypeptide variant comprises two introduced in vivo N-glycosylation sites created by a substitution selected from the group consisting of T106N, I205T and V253N.

### Claim 16 (depends on 1)

The method claim 1, wherein the polypeptide variant comprises a substitution in at least one position selected from the group consisting of L39, I42, S43, K62, L65, F71, E82 and F275.

### Claim 17 (depends on 1)

The method claim 1, wherein the polypeptide variant is conjugated to at least one polyethylene glycol (PEG) polymer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the polypeptide variant is conjugated to up to eight PEG polymers.

### Claim 19 (depends on 17)

The method of claim 17, wherein the polypeptide variant comprises at least one PEG polymer conjugated to a lysine residue or the N-terminal.

### Claim 20 (depends on 17)

The method of claim 17, wherein the polypeptide variant comprises at least one PEG polymer conjugated to a cysteine residue.

### Claim 21 (depends on 1)

The method of claim 1, wherein the polypeptide variant is in its activated form.

### Claim 22 (depends on 1)

The method of claim 1, wherein the ratio between the activity of the polypeptide variant, in its activated form, and the activity of rhFVIIa is at least about 2 when assayed in the “TF-independent Factor X Activation Assay”.

### Claim 23 (depends on 1)

The method of claim 1, wherein the ratio between the activity of the polypeptide variant, in its activated form, and the activity of rhFVIIa is at the most 0.9 when assayed in the “Whole Blood Assay”.

### Claim 24 (depends on 1)

The method of claim 1, wherein the polypeptide is administered in the activated form.

### Claim 25 (depends on 1)

The method of claim 1, wherein the polypeptide is administered in the non-activated form.

### Claim 26

(canceled)
